ES2139093T3 - Antimicrobianos del tipo de oxazin- y tiazin-oxazolidinonas sustituidas. - Google Patents

Antimicrobianos del tipo de oxazin- y tiazin-oxazolidinonas sustituidas.

Info

Publication number
ES2139093T3
ES2139093T3 ES94925765T ES94925765T ES2139093T3 ES 2139093 T3 ES2139093 T3 ES 2139093T3 ES 94925765 T ES94925765 T ES 94925765T ES 94925765 T ES94925765 T ES 94925765T ES 2139093 T3 ES2139093 T3 ES 2139093T3
Authority
ES
Spain
Prior art keywords
c8alkoxy
spp
mycobacterium
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925765T
Other languages
English (en)
Inventor
Michael R Barbachyn
Steven J Brickner
Douglas K Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2139093T3 publication Critical patent/ES2139093T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO DE FORMULA ESTRUCTURAL (I) O SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO EN DONDE: X ES O, S, SO, SO{SUB,2}, SNR{SUP,10} O S(O)NR{SUP,10}; R ES (A) HIDROGENO, (B) ALQUILO C{SUB,1}-C{SUB,8} OPCIONALMENTE SUSTITUIDO CON UNO O MAS DE LOS SIGUIENTES: F, CL, HIDROXI, C{SUB,1}-C{SUB,8}ALCOXI, C{SUB,1}-C{SUB,8}ACILOXI O -O-CH{SUB,2}-PH, (C) C{SUB,3}C{SUB,6}CICLOALQUILO, (D) AMINO, (E) C{SUB,1}C{SUB,8}ALQUILAMINO, (F) C{SUB,1}-C{SUB,8}DIALQUILAMINO O (G) C{SUB,1}-C{SUB,8}ALCOXI; R{SUP,1} ES H, EXCEPTO CUANDO X ES O, ENTONCES R{SUP,1} PUEDE SER H, CH{SUB,3}, CN, CO{SUB,2}H, CO{SUB,2}R O (CH{SUB,2}){SUB,M}R{SUP,11} (M ES 1 O 2); R{SUP,2} ES INDEPENDIENTEMENTE H, F O CL; R{SUP,3} ES H EXCEPTO CUANDO X ES O Y R{SUP,1} ES CH{SUB,3}, ENTONCES R{SUP,3} PUEDE SER H O CH{SUB,3}; R{SUP,10} ES INDEPENDIENTEMENTE H, C{SUB,1}C{SUB,4}ALQUILO (OPCIONALMENTE SUSTITUIDO CON CLORO, FLUOR, HIDROXI, C{SUB,1}-C{SUB,8}ALCOXI, AMINO, C{SUB,1}C{SUB,8}ALQUILAMINO, O C{SUB,1}-C{SUB,8}DIALQUILAMINO) O PTOLUENOSULFONILO; R{SUP,11} ES HIDROGENO, OH, OR, OCOR, NH{SUB,2}, NHCOR O N(R{SUP,10}){SUB,2}; Y N ES 0, 1, O 2. LOS DERIVADOS DE OXAZINA Y OXAZOLIDINONA DE TIAZINA SON UTILES COMO AGENTES ANTIMICROBIALES, EFECTIVOS FRENTE A UN NUMERO DE PATOGENOS HUMANOS Y VETERINARIOS, INCLUYENDO BACTERIAS AEROBICAS GRAM-POSITIVAS COMO ESTAFILOCOCOS, ESTREPTOCOCOS Y ENTEROCOCOS CON MULTIPLE RESISTENCIA ASI COMO ORGANISMOS ANAEROBICOS COMO ESPECIES DE BACTEROIDES SPP. Y CLOSTRIDIA SPP., Y ORGANISMOS DE ACIDO RAPIDO COMO MYCOBACTERIUM TUBERCULOSIS, MYCOBACTERIUM AVIUM Y MYCOBACTERIUM SPP.
ES94925765T 1993-09-09 1994-08-16 Antimicrobianos del tipo de oxazin- y tiazin-oxazolidinonas sustituidas. Expired - Lifetime ES2139093T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11927993A 1993-09-09 1993-09-09
US22615894A 1994-04-11 1994-04-11

Publications (1)

Publication Number Publication Date
ES2139093T3 true ES2139093T3 (es) 2000-02-01

Family

ID=26817181

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94925765T Expired - Lifetime ES2139093T3 (es) 1993-09-09 1994-08-16 Antimicrobianos del tipo de oxazin- y tiazin-oxazolidinonas sustituidas.

Country Status (20)

Country Link
EP (1) EP0717738B1 (es)
JP (1) JP3176630B2 (es)
KR (1) KR100301269B1 (es)
CN (1) CN1057087C (es)
AT (1) ATE185804T1 (es)
AU (1) AU687866B2 (es)
CA (1) CA2168560C (es)
DE (2) DE10299007I2 (es)
DK (1) DK0717738T3 (es)
ES (1) ES2139093T3 (es)
GR (1) GR3031809T3 (es)
IL (1) IL110802A (es)
LV (1) LV12605B (es)
MY (1) MY115155A (es)
NL (1) NL300079I1 (es)
NZ (1) NZ271805A (es)
PH (1) PH31634A (es)
SI (1) SI0717738T1 (es)
TW (1) TW293817B (es)
WO (1) WO1995007271A1 (es)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233766T1 (de) * 1994-11-15 2003-03-15 Upjohn Co Antibakterielle bizyklische oxazin und thiazin- oxazolidinone
JPH10513446A (ja) * 1995-02-03 1998-12-22 ファルマシア・アンド・アップジョン・カンパニー ヘテロ芳香族環置換フェニルオキサゾリジノン抗微生物剤
ES2162047T3 (es) * 1995-05-11 2001-12-16 Upjohn Co Oxazolidinonas con resto diazinilo y carbazinilo espirociclico y biciclico.
PT1019385E (pt) * 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
WO1997010235A1 (en) * 1995-09-15 1997-03-20 Pharmacia & Upjohn Company 5-AMIDOMETHYL α, β-SATURATED AND -UNSATURATED 3-ARYL BUTYROLACTONE ANTIBACTERIAL AGENTS
GB9521508D0 (en) * 1995-10-20 1995-12-20 Zeneca Ltd Chemical compounds
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
GB9604301D0 (en) * 1996-02-29 1996-05-01 Zeneca Ltd Chemical compounds
PT1114819E (pt) * 1996-04-11 2008-02-28 Pharmacia & Upjohn Co Llc Processo para preparação de oxazolidinonas
GB9609919D0 (en) * 1996-05-11 1996-07-17 Zeneca Ltd Chemical compounds
DE19709443C1 (de) * 1997-03-07 1998-10-08 Clariant Gmbh Verfahren zur Herstellung von N-Carboxyalkyl-3-fluor-4-dialkylaminoanilinen und N-Carboxymethyl-3-fluor-4-morpholinoanilin und N-Carboxyisobutyl-3-fluor-4-morpholinoanilin
ATE293609T1 (de) 1997-05-30 2005-05-15 Upjohn Co Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
GB9717807D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
HUP0004388A3 (en) 1997-11-07 2001-10-29 Upjohn Co Process for the preparation of oxazolidinones, intermediates and preparation thereof
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
WO1999037630A1 (en) * 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
NZ506292A (en) * 1998-02-13 2003-05-30 Upjohn Co Substituted aminophenyl isoxazoline methylamide derivatives useful as antimicrobials
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000029396A1 (de) * 1998-11-17 2000-05-25 Bayer Aktiengesellschaft Neue substituierte phenyloxazolidon-derivate
WO2000032599A1 (en) * 1998-11-27 2000-06-08 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6608081B2 (en) 1999-08-12 2003-08-19 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US6297242B1 (en) 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
US6518285B2 (en) * 1999-12-21 2003-02-11 Ortho Mcneil Pharmaceutical, Inc. Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials
JP2003518117A (ja) * 1999-12-21 2003-06-03 ファルマシア・アンド・アップジョン・カンパニー スルホキシミン官能基を有するオキサゾリジノンおよび抗微生物剤としてのその使用
KR100355345B1 (ko) * 2000-01-21 2002-10-12 한국과학기술연구원 티오펜환을 함유한 신규한 옥사졸리디논 유도체, 그의 제조방법 및 조성물
AR027261A1 (es) * 2000-02-02 2003-03-19 Upjohn Co Linezolid forma cristalina ii
US6642238B2 (en) 2000-02-10 2003-11-04 Pharmacia And Upjohn Company Oxazolidinone thioamides with piperazine amide substituents
US6562820B2 (en) * 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
US6638908B1 (en) 2000-08-09 2003-10-28 Yale University Crystals of the large ribosomal subunit
US6947844B2 (en) 2000-08-09 2005-09-20 Yale University Modulators of ribosomal function and identification thereof
US6833453B2 (en) 2000-10-17 2004-12-21 Pharmacia & Upjohn Company Methods of producing oxazolidinone compounds
US7160912B2 (en) 2000-12-26 2007-01-09 Dr.Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
EP1358185A2 (en) * 2001-02-07 2003-11-05 Ortho-Mcneil Pharmaceutical, Inc. Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
GB0108794D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compound
GB0108793D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
ES2268011T3 (es) * 2001-04-07 2007-03-16 Astrazeneca Ab Oxazolidinonas que contienen un grupo sulfonimida como antibioticos.
GB0108764D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
CA2439959A1 (en) 2001-04-20 2002-10-31 Pharmacia & Upjohn Company A method for the preparation of oxazolidinones
ES2186550B2 (es) 2001-06-27 2003-11-16 Vita Lab Nuevos derivados de oxazolidinonas como antibacterianos.
MXPA04000294A (es) * 2001-07-10 2004-05-04 Pharmacia & Upjhon Company Tiacin oxazolidinonas cristalinas.
US6952650B2 (en) 2001-08-03 2005-10-04 Yale University Modulators of ribosomal function and identification thereof
IL151012A0 (en) 2001-08-03 2003-02-12 Ribosomes Structure And Protei Ribosomes structure and protein synthesis inhibitors
WO2003062231A1 (en) * 2002-01-24 2003-07-31 Pharmacia & Upjohn Company Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones
US7141588B2 (en) 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
KR20040087329A (ko) 2002-02-28 2004-10-13 아스트라제네카 아베 3-시클릴-5-(질소-함유 5-원 고리) 메틸-옥사졸리디논유도체 및 그의 항균제로서의 용도
JP2005531504A (ja) 2002-02-28 2005-10-20 アストラゼネカ アクチボラグ 化学化合物
AU2003224345A1 (en) * 2002-04-30 2003-11-17 Orchid Chemicals & Pharmaceuticals Antibacterial agents
CA2491287A1 (en) 2002-08-12 2004-02-19 Pharmacia & Upjohn Company N-aryl-2-oxazolidinones and their derivatives
WO2004026848A1 (en) * 2002-09-20 2004-04-01 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ATE344036T1 (de) 2002-11-21 2006-11-15 Pharmacia & Upjohn Co Llc N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinon-5- carbonsäureamid-derivate und verwandte verbindungen als antibakterielle mittel
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
BRPI0409217A (pt) 2003-04-09 2006-03-28 Pharmacia & Upjohn Co Llc derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
JP4256744B2 (ja) * 2003-08-14 2009-04-22 三菱レイヨン株式会社 （メタ）アクリル系重合体の製造方法
US7687627B2 (en) * 2003-09-08 2010-03-30 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy
US7304050B2 (en) 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
DK1673370T3 (da) 2003-10-16 2009-12-07 Symed Labs Ltd Krystallingsk form af linezolid
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
CN102816194A (zh) 2004-02-27 2012-12-12 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
WO2005113520A1 (en) * 2004-05-20 2005-12-01 Pharmacia & Upjohn Company Llc Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
JP2007504173A (ja) * 2004-06-29 2007-03-01 テバ ファーマシューティカル インダストリーズ リミティド リネゾリドのｉｖ型結晶
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
ES2335307T3 (es) 2005-06-29 2010-03-24 PHARMACIA & UPJOHN COMPANY LLC Homomorfolin oxalidinonas como agentes antibacterianos.
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
CA2647605A1 (en) * 2006-03-31 2007-10-11 Research Foundation Itsuu Laboratory Novel compound having heterocyclic ring
CN102442970A (zh) 2006-05-31 2012-05-09 雅培制药有限公司 用作大麻素受体配位体的噻唑化合物及其用途
CN101448800A (zh) 2006-05-31 2009-06-03 艾博特公司 作为大麻素受体配体的新型化合物及其用途
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN101765594A (zh) 2007-03-28 2010-06-30 雅培制药有限公司 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2008144360A1 (en) 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
EP2033960A3 (en) 2007-09-04 2009-04-29 Dipharma Francis S.r.l. Linezolid crystalline hydrate form and linezolid salts
US20090093631A1 (en) * 2007-09-06 2009-04-09 Ben-Zion Dolitzky Processes for the preparation of a linezolid intermediate, linezolid hydroxide
EP2208729A4 (en) 2007-10-02 2011-04-27 Res Found Itsuu Lab OXAZOLIDINONE DERIVATIVE WITH 7-CHAIN HETEROCYCLE
WO2009063505A2 (en) * 2007-10-08 2009-05-22 Usv Limited Process for preparation of (s) (n-[[3-[3-fluoro-4-(4-morpholinyl) hen l -2-oxo-5-oxazolidin l methyl]acetamide
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
ITMI20072359A1 (it) 2007-12-18 2009-06-19 Dipharma Francis Srl Procedimento per la preparazione di derivati ossazolidinonici
EP2274306A1 (en) 2008-03-11 2011-01-19 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009157423A1 (ja) 2008-06-24 2009-12-30 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
US8173687B2 (en) 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8188135B2 (en) 2008-09-16 2012-05-29 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2163547A1 (en) 2008-09-16 2010-03-17 Unión Químico Farmacéutica, S.A. (UQUIFA) Process for the preparation of an oxazolidinone antibacterial agent and intermediates thereof
KR101023174B1 (ko) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
WO2010042887A2 (en) 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
WO2010045401A1 (en) 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
WO2010045402A1 (en) 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
LT2376480T (lt) 2008-12-05 2016-09-12 Abbvie Inc. Sulfonamido dariniai kaip bcl-2-selektyviąją apoptozę sukeliantys agentai, skirti vėžio ir imuninių ligų gydymui
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
CN101774978B (zh) 2009-01-13 2011-09-21 联化科技股份有限公司 一种利奈唑胺的制备方法及其中间体
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
SG193849A1 (en) 2009-01-19 2013-10-30 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120585A1 (es) 2009-02-03 2012-06-13 Trius Therapeutics Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofensil)-5-hidroximetil oxazolidin-2-ona
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
JP2012522004A (ja) 2009-03-27 2012-09-20 アボット・ラボラトリーズ カンナビノイド受容体リガンドである化合物
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010111574A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201704742YA (en) 2009-05-26 2017-07-28 Abbvie Ireland Unlimited Co Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2010138828A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
WO2011029460A1 (en) * 2009-09-09 2011-03-17 Synthon B.V. Nonhygroscopic linezolid salts
US20110095033A1 (en) 2009-10-28 2011-04-28 Belkin International, Inc. Portable Multi-Media Communication Device Protective Carrier and Method of Manufacture Therefor
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
MX2012006036A (es) 2009-11-25 2012-06-19 Abbott Lab Moduladores del canal del calcio.
TW201130855A (en) 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
SG10201406608YA (en) 2010-03-25 2014-12-30 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
WO2011159785A1 (en) 2010-06-15 2011-12-22 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
CN103140476A (zh) 2010-08-10 2013-06-05 Abbvie公司 新颖的trpv3调节剂
EP2603505A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
KR20140009251A (ko) 2010-11-15 2014-01-22 애브비 인코포레이티드 Ｎａｍｐｔ 및 ｒｏｃｋ 억제제
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
CN107266435A (zh) 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
CN103402521B (zh) 2010-11-23 2016-01-20 艾伯维巴哈马有限公司 使用选择性的bcl-2抑制剂的治疗方法
KR101264903B1 (ko) * 2010-11-24 2013-05-15 한국과학기술연구원 2-피롤리돈기를 포함하는 옥사졸리디논 유도체 또는 이의 약학적으로 허용 가능한 염 및 이들의 제조방법
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN102617500B (zh) * 2011-01-31 2016-07-13 山东信立泰药业有限公司 一种利奈唑胺中间体、其制备方法和利奈唑胺的制备方法
WO2012104874A2 (en) * 2011-02-02 2012-08-09 Mylan Laboratories Limited. Aqueous concentrated formulation of linezolid
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
EP2683696A1 (en) 2011-03-09 2014-01-15 Synthon BV Process for making crystalline form a of linezolid
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
JP5934778B2 (ja) 2011-03-25 2016-06-15 アッヴィ・インコーポレイテッド Ｔｒｐｖ１拮抗薬
CN102229577A (zh) * 2011-05-11 2011-11-02 石药集团中诺药业（石家庄）有限公司 利奈唑胺中间体的制备及纯化方法
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
KR101271224B1 (ko) 2011-07-05 2013-06-10 한국과학기술연구원 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법
TW201319049A (zh) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
WO2013072923A1 (en) 2011-09-19 2013-05-23 Cadila Healthcare Limited Process for the preparation of crystalline linezolid
WO2013054275A1 (en) * 2011-10-11 2013-04-18 Council Of Scientific & Industrial Research Sila analogs of oxazolidinone derivatives and synthesis thereof
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
MX2014004979A (es) 2011-10-24 2014-10-24 Abbvie Inc Derivados de metanol como moduladores de trpv3.
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
EP2780328A1 (en) 2011-11-18 2014-09-24 Abbvie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
WO2013111048A1 (en) * 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN103254148B (zh) 2012-02-15 2016-04-13 浙江海正药业股份有限公司 利奈唑胺中间体的制备方法
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
CN102643251B (zh) * 2012-04-17 2016-08-10 四川美大康佳乐药业有限公司 利奈唑胺的降解杂质及其制备方法
WO2013155695A1 (en) 2012-04-20 2013-10-24 Abbott Laboratories Isoindolone derivatives
CN102702125B (zh) * 2012-05-10 2014-09-03 浙江工业大学 一种利奈唑胺的化学合成方法
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
JP2015516437A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬として使用されるチアゾールカルボキサミド誘導体
KR20150007349A (ko) 2012-05-11 2015-01-20 애브비 인코포레이티드 Nampt 억제제
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
CA2874953A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103570639B (zh) * 2012-08-08 2016-02-03 成都国弘医药有限公司 一种利奈唑胺的合成方法
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
IN2015DN02070A (es) 2012-09-14 2015-08-14 Abbvie Deutschland
EP2917189B1 (en) 2012-11-09 2016-08-17 Synthon BV Process for making linezolid
CN103896963B (zh) * 2012-12-26 2017-06-09 中国科学院上海药物研究所 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
WO2014118809A1 (en) 2013-01-29 2014-08-07 Actavis Group Ptc Ehf. Pharmaceutical composition with linezolid
US9650358B2 (en) 2013-03-13 2017-05-16 Abbvie Inc. Pyridine CDK9 kinase inhibitors
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
US9346813B2 (en) 2013-03-14 2016-05-24 Abbvie Inc. Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
CN105339366A (zh) 2013-03-14 2016-02-17 艾伯维德国有限责任两合公司 带有取代的氧杂环丁烷的2-吲哚酮衍生物及其治疗血管加压素相关疾病的用途
MX2015012896A (es) 2013-03-14 2016-06-02 Abbvie Inc Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
AU2014230745A1 (en) 2013-03-14 2015-09-03 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10A
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105764895A (zh) 2013-10-17 2016-07-13 艾伯维德国有限责任两合公司 氨基四氢化萘及氨基二氢化茚衍生物，包含其的药物组合物及其在治疗中的用途
SG11201602982YA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015068121A1 (en) 2013-11-06 2015-05-14 Unimark Remedies Ltd. Process for preparation of crystalline form i of linezolid and its compositions
WO2015068171A1 (en) * 2013-11-08 2015-05-14 Lee Pharma Limited Novel oxazolidinone compounds
CN105705147B (zh) * 2013-11-08 2019-06-28 李药业有限公司 新颖的噁唑烷酮抗菌化合物
US9840495B2 (en) 2013-12-20 2017-12-12 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015119712A1 (en) 2014-02-06 2015-08-13 Abbvie Inc. Tetracyclic cdk9 kinase inhibitors
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20180243298A1 (en) 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
EA202190167A1 (ru) * 2015-07-17 2021-07-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Замещенные фенилоксазолидиноны для антимикробной терапии
KR101660874B1 (ko) 2015-09-04 2016-09-30 주식회사 알에스텍 리네졸리드의 제조방법 및 그 중간체
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2017089458A1 (en) 2015-11-25 2017-06-01 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
US10995097B2 (en) 2016-03-11 2021-05-04 The Board Of Trustees Of The University Of Illinois Small molecules active against gram-negative bacteria
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
US11168078B2 (en) 2016-11-28 2021-11-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
EP3601255A1 (en) 2017-03-21 2020-02-05 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
US11274106B2 (en) 2017-06-23 2022-03-15 The Board Of Trustees Of The University Of Illinois Topoisomerase inhibitors with antibacterial and anticancer activity
BR112020018444A2 (pt) 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases
EP3768661B1 (en) 2018-03-23 2024-05-01 Fochon Pharmaceuticals, Ltd. Deuterated compounds as rock inhibitors
CN108997247A (zh) * 2018-08-10 2018-12-14 泰州申合泰尔生物医药有限公司 一种利伐沙班中间体的制备方法
CN112409286B (zh) 2019-08-20 2022-08-05 杭州迪克科技有限公司 一种n-取代苯基-5-羟甲基-2-噁唑烷酮的合成方法
CN114957232B (zh) * 2021-05-28 2023-06-30 四川大学 一种苯并二氢恶嗪类化合物及其制备方法和抗结核的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54160371A (en) * 1978-06-02 1979-12-19 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative and hypotensive agents comprising it
ES8506659A1 (es) * 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1260948A (en) * 1984-12-05 1989-09-26 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny

Also Published As

Publication number Publication date
DE10299007I1 (de) 2002-07-04
IL110802A (en) 2000-09-28
AU7557094A (en) 1995-03-27
EP0717738A1 (en) 1996-06-26
SI0717738T1 (en) 2000-02-29
DE69421285D1 (de) 1999-11-25
MY115155A (en) 2003-04-30
DK0717738T3 (da) 2000-05-08
TW293817B (es) 1996-12-21
DE69421285T2 (de) 2000-02-24
CA2168560A1 (en) 1995-03-16
LV12605A (en) 2001-01-20
EP0717738B1 (en) 1999-10-20
WO1995007271A1 (en) 1995-03-16
CN1130379A (zh) 1996-09-04
CA2168560C (en) 2001-08-14
ATE185804T1 (de) 1999-11-15
CN1057087C (zh) 2000-10-04
KR960704866A (ko) 1996-10-09
PH31634A (en) 1999-01-12
NL300079I1 (nl) 2002-04-02
AU687866B2 (en) 1998-03-05
IL110802A0 (en) 1994-11-11
NZ271805A (en) 1998-02-26
JP3176630B2 (ja) 2001-06-18
LV12605B (en) 2001-05-20
JPH09502436A (ja) 1997-03-11
DE10299007I2 (de) 2008-09-18
GR3031809T3 (en) 2000-02-29
KR100301269B1 (ko) 2001-10-22

Similar Documents

Publication Publication Date Title
ES2139093T3 (es) Antimicrobianos del tipo de oxazin- y tiazin-oxazolidinonas sustituidas.
DE69529838D1 (de) Antibakterielle bizyklische oxazin und thiazin-oxazolidinone
DK0788498T3 (da) Phenyloxazolidinoner med antimikrobiel virkning
DK0874852T3 (da) Antibakterielt oxazolidinonmiddel med tricykliske substituenter
PT863890E (pt) Agentes antibacterianos de 5-amidometil-3-arilbutirolactona alfa,beta-saturados e insaturados
MX9703040A (es) Antimicrobianos de feniloxazolidinona.
TH77466EX (th) สารต่อต้านการเจริญเติบโตของจุลินทรีย์ที่เป็นซับสทิทิวเทดออกซาซีน และไธแอซีนออกซาโซลิดิโนน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 717738

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: LINEZOLID (ZYVOXID).

Spc suppl protection certif: C200200002

Filing date: 20020118

SPCG Supplementary protection certificate granted

Free format text: LINEZOLID (ZYVOXID).

Spc suppl protection certif: C200200002

Filing date: 20020118

Expiry date: 20160105

Effective date: 20040914